Femasys (FEMY) Income from Continuing Operations (2020 - 2025)
Femasys (FEMY) reported Income from Continuing Operations of 4585922.0 for Q2 2025, up 2.11% on a YoY basis from 4491339.31 in Q2 2024, and up 22.23% quarter-over-quarter from 5896839.0 in Q1 2025.
Femasys (FEMY) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Femasys has reported Income from Continuing Operations for 6 years, with the latest figure at 4585922.0 in Q2 2025.
- For the quarter ending Q2 2025, Income from Continuing Operations rose 2.11% year-over-year to 4585922.0; the trailing twelve-month figure through Jun 2025 stood at 21015305.0 (down 25.9% YoY), and the FY2025 full-year result was 18627887.0, up 1.0% from the prior year.
- Income from Continuing Operations for Q2 2025 stood at 4585922.0, up from 5896839.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1083059.0 in Q2 2021, with the low at 5896839.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 3470551.22 across 5 years, with a median of 2959739.0 in 2022.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations advanced 27.09% — and 2022, when it tumbled 143.21%.
- Femasys' Income from Continuing Operations stood at 2364853.0 in 2021, then slipped by 22.43% to 2895212.0 in 2022, then tumbled by 52.34% to 4410454.0 in 2023, then dropped by 16.17% to 5123684.0 in 2024, then grew by 10.5% to 4585922.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4585922.0 (Q2 2025), 5896839.0 (Q1 2025), and 5123684.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 826.00 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -37.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 239.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 398.73 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 135.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 13.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 112.77 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -17.00 Mn |
| 10 | Femasys | 254.59 Mn | 249.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -2.95 Mn |
| Dec 31, 2022 | -2.90 Mn |
| Sep 30, 2022 | -2.97 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.57 Mn |